Chennai: People whose immune systems mount an unusually aggressive early response to tuberculosis may be less likely to respond well to standard drug .
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into ...
A team led by the University of Sydney has identified red blood cell rupture at dying endothelial sites as a primary driver of microvascular obstruction in COVID-19, bypassing the expected role of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results